ProPhase Labs (PRPH) Competitors $0.43 +0.00 (+0.40%) Closing price 04:00 PM EasternExtended Trading$0.41 -0.01 (-2.87%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRPH vs. GNTA, VNRX, ANEB, PYXS, ADAP, PYRGF, VRCA, CNTB, STRO, and IKNAShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Genenta Science (GNTA), VolitionRx (VNRX), Anebulo Pharmaceuticals (ANEB), Pyxis Oncology (PYXS), Adaptimmune Therapeutics (ADAP), PyroGenesis Canada (PYRGF), Verrica Pharmaceuticals (VRCA), Connect Biopharma (CNTB), Sutro Biopharma (STRO), and Ikena Oncology (IKNA). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. Its Competitors Genenta Science VolitionRx Anebulo Pharmaceuticals Pyxis Oncology Adaptimmune Therapeutics PyroGenesis Canada Verrica Pharmaceuticals Connect Biopharma Sutro Biopharma Ikena Oncology Genenta Science (NASDAQ:GNTA) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations. Is GNTA or PRPH more profitable? Genenta Science's return on equity of 0.00% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets Genenta ScienceN/A N/A N/A ProPhase Labs N/A -184.38%-64.59% Do institutionals and insiders believe in GNTA or PRPH? 15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor GNTA or PRPH? In the previous week, Genenta Science had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 2 mentions for Genenta Science and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 1.87 beat Genenta Science's score of 1.23 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Overall Sentiment Genenta Science Positive ProPhase Labs Very Positive Which has preferable valuation and earnings, GNTA or PRPH? Genenta Science has higher earnings, but lower revenue than ProPhase Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenenta ScienceN/AN/A-$9.64MN/AN/AProPhase Labs$5.85M3.02-$53.36M-$1.26-0.34 Do analysts rate GNTA or PRPH? Genenta Science presently has a consensus target price of $25.00, indicating a potential upside of 561.38%. Given Genenta Science's stronger consensus rating and higher probable upside, equities research analysts plainly believe Genenta Science is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, GNTA or PRPH? Genenta Science has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.41, suggesting that its stock price is 141% less volatile than the S&P 500. SummaryGenenta Science beats ProPhase Labs on 10 of the 12 factors compared between the two stocks. Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.66M$2.42B$5.53B$9.13BDividend YieldN/A1.81%5.06%4.01%P/E Ratio-0.349.2128.5819.57Price / Sales3.02461.46372.6479.65Price / CashN/A22.3424.7227.51Price / Book1.704.708.235.56Net Income-$53.36M$30.99M$3.19B$252.37M7 Day Performance-3.82%7.04%5.46%3.11%1 Month Performance28.34%22.46%9.39%11.74%1 Year Performance-87.10%-2.80%30.48%17.41% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs0.5408 of 5 stars$0.43+0.4%N/A-87.1%$17.66M$5.85M-0.34130Positive NewsGNTAGenenta Science2.6317 of 5 stars$3.98+4.7%$25.00+528.1%+19.3%$69.50MN/A0.007Gap UpVNRXVolitionRx2.1303 of 5 stars$0.67-9.0%$3.50+419.8%+1.3%$69.38M$1.31M-1.8780ANEBAnebulo Pharmaceuticals2.7312 of 5 stars$1.65-2.1%$5.50+234.3%-32.8%$69.02MN/A-6.334High Trading VolumePYXSPyxis Oncology2.306 of 5 stars$1.14+3.6%$9.00+689.5%-63.2%$68.14MN/A-0.7260ADAPAdaptimmune Therapeutics1.9764 of 5 stars$0.24-3.6%$1.35+460.6%-79.0%$66.26M$178.03M-0.89490PYRGFPyroGenesis Canada0.0896 of 5 stars$0.35+4.0%N/A-54.8%$66.16M$9.14M-5.9190VRCAVerrica Pharmaceuticals4.4943 of 5 stars$0.83+17.4%$8.00+863.9%-90.5%$65.36M$7.57M-0.6940Gap DownCNTBConnect Biopharma3.1195 of 5 stars$1.14-2.5%$7.00+514.0%+21.6%$64.97M$26.03M0.00110STROSutro Biopharma4.3 of 5 stars$0.74-2.9%$6.11+725.4%-81.7%$64.46M$62.04M-0.25240IKNAIkena Oncology2.7855 of 5 stars$1.35+1.5%$3.00+122.2%-19.3%$64.18M$9.16M-1.5770Gap Up Related Companies and Tools Related Companies GNTA Competitors VNRX Competitors ANEB Competitors PYXS Competitors ADAP Competitors PYRGF Competitors VRCA Competitors CNTB Competitors STRO Competitors IKNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRPH) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.